HUPO Connect 2020 kicks off with a series of 60-minute webinars taking place in July, August and September in which the very best of proteomics research will be presented as a prelude to the main Congress sessions. All webinars are free for HUPO Members, and $10.00 USD for Non HUPO Members. Non Members can sign up for HUPO's Mailing List during the registration process and receive complimentary registration!
Mark your calendars for Thursday, August 20, 2020 for our second Pre-Congress Webinar!
Attendees will be able to submit questions and/or comments via a text chat feature and a live audio Q&A facilitated by the Session Chair will take place immediately following the presentations.
Date: Thursday, August 20, 2020
Time: 07:00 PDT (UTC-7), 10:00 EDT (UTC-4), 14:00 UTC, 22:00 CST (UTC+8), 00:00 AEST (UTC+10). Note that UTC stands for Coordinated Universal Time.
Register for the Webinar
This webinar will be moderated by Stephen Pennington and will branch into two presentations with two featured speakers. Our confirmed speakers include Jenny Van Eyk and Nathan Price. More information will be announced soon.
In order to learn more about each individual speaker, please click on the photos below.
Stephen Pennington graduated from Imperial College of Science and Technology with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. Subsequently, he was an Elmore Medical Research Fellow in the Department of Biochemistry in Cambridge University. His small research team in University College Dublin (UCD; www.ucd.ie) is developing multiplexed protein biomarker measurements to support the discovery and translation of novel blood protein biomarkers to clinical diagnostic tests. Late in 2016, Steve founded the UCD spin out company, Atturos (www.Atturos.com) and was awarded UCD's Innovator of the Year in 2018. Atturos aims to develop and deliver advanced clinical diagnostic tests that will underpin better patient outcomes. In 2017, Steve was the lead organiser of the 16th Human Proteome Organisation (HUPO) World Congress, which was held in Dublin and included a Gala Dinner at which former US Vice-President Joe Biden was guest speaker. Steve is currently Professor of Proteomics and Senior Fellow, UCD Conway Institute and President of HUPO.
Dr. Nathan Price is Professor & Associate Director of the Institute for Systems Biology in Seattle where he co-directs with Lee Hood the Hood-Price Integrated Lab for Systems Biomedicine. He was selected as one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine in 2019, is a Camille Dreyfus Teacher-Scholar, and received the 2016 Grace A. Goldsmith award for his work pioneering scientific wellness. He is active in entrepreneurship, having co-founded 2 companies (Aevum Aging and Arivale). He is a Trustee of the Health and Environmental Sciences Institute, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the European Society of Preventive Medicine, and on the Board of Advisors for the American Cancer Society (WA). He also served as Chair of the NIH Study Section on Modeling and Analysis of Biological Systems (MABS) from 2018-2020.
Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Her laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.
Keep up to date with Official Congress News